Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Gaetano Aurilio, Matteo Santoni, Alessia Cimadamore, Francesco Massari, Marina Scarpelli, Antonio Lopez-Beltran, Liang Cheng, Nicola Battelli, Franco Nolé & Rodolfo Montironi. (2020) Renal Cell Carcinoma: genomic landscape and clinical implications. Expert Review of Precision Medicine and Drug Development 5:2, pages 95-100.
Read now
Read now
Costanza Canino, Lorenzo Perrone, Eugenia Bosco, Giuseppe Saltalamacchia, Alessandra Mosca, Mimma Rizzo & Camillo Porta. (2019) Targeting angiogenesis in metastatic renal cell carcinoma. Expert Review of Anticancer Therapy 19:3, pages 245-257.
Read now
Read now
Sumanta K. Pal, Eric Jonasch, James E. Signorovitch, William M. Reichmann, Nanxin Li, Zhimei Liu, Jose Ricardo Perez & Nicholas J. Vogelzang. (2016) Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US. Journal of Medical Economics 19:5, pages 462-468.
Read now
Read now
Eric Jonasch, James E. Signorovitch, Peggy L. Lin, Zhimei Liu, Ken Culver, Sumanta K. Pal, Jeffrey A. Scott & Nicholas J. Vogelzang. (2014) Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices. Current Medical Research and Opinion 30:10, pages 2041-2050.
Read now
Read now
Articles from other publishers (24)
Matteo Santoni, Francesco Massari, Sergio Bracarda, Enrique Grande, Marc R. Matrana, Mimma Rizzo, Ugo De Giorgi, Umberto Basso, Gaetano Aurilio, Lorena Incorvaia, Angelo Martignetti, Javier Molina-Cerrillo, Veronica Mollica, Alessandro Rizzo & Nicola Battelli. (2022) Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors. European Urology Focus 8:6, pages 1696-1702.
Crossref
Crossref
Camillo Porta, Vittorio Ferrari, Paolo A. Zucali, Giuseppe Fornarini, Antonio Bernardo, Andrea Falconeri, Sandra Santarossa, Carmine Tinelli, Mimma Rizzo, Giovanni Pappagallo & Alessandra Bearz. (2022) Prospective phase II study of sunitinib rechallenge in metastatic renal cell carcinoma: The “retry” study from the Italian Group of Onco-Nephrology (G.I.O.N.). Journal of Onco-Nephrology 6:3, pages 107-114.
Crossref
Crossref
Hossam Kamli, Evan P. Owens, David A. Vesey, Rajagopalan Prasanna, Li Li, Glenda C. Gobe & Christudas Morais. (2022) Overcoming sunitinib resistance with tocilizumab in renal cell carcinoma: Discordance between in vitro and in vivo effects. Biochemical and Biophysical Research Communications 586, pages 42-48.
Crossref
Crossref
Tony J. Chen, Piotr Mydel, Małgorzata Benedyk‐Machaczka, Marta Kamińska, Urszula Kalucka, Magnus Blø, Jessica Furriol, Gro Gausdal, James Lorens, Tarig Osman & Hans‐Peter Marti. (2021) AXL targeting by a specific small molecule or monoclonal antibody inhibits renal cell carcinoma progression in an orthotopic mice model. Physiological Reports 9:23.
Crossref
Crossref
Qinhan Li, Zhenan Zhang, Yu Fan & Qian Zhang. (2021) Epigenetic Alterations in Renal Cell Cancer With TKIs Resistance: From Mechanisms to Clinical Applications. Frontiers in Genetics 11.
Crossref
Crossref
L. Hamieh, R. L. Beck, V. H. Le & J. J. Hsieh. (2020) The efficacy of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma exhibiting primary resistance to front-line targeted therapy or immunotherapy. Cancer Urology 16:3, pages 53-61.
Crossref
Crossref
Lana Hamieh, Rachel L. Beck, Valerie H. Le & James J. Hsieh. (2020) The Efficacy of Lenvatinib Plus Everolimus in Patients with Metastatic Renal Cell Carcinoma Exhibiting Primary Resistance to Front-Line Targeted Therapy or Immunotherapy. Clinical Genitourinary Cancer 18:4, pages 252-257.e2.
Crossref
Crossref
Yonghyo Kim, Yutaka Sugihara, Tae Young Kim, Sung Min Cho, Jin Young Kim, Ju Yeon Lee, Jong Shin Yoo, Doona Song, Gyoonhee Han, Melinda Rezeli, Charlotte Welinder, Roger Appelqvist, György Marko-Varga & Ho Jeong Kwon. (2020) Identification and Validation of VEGFR2 Kinase as a Target of Voacangine by a Systematic Combination of DARTS and MSI. Biomolecules 10:4, pages 508.
Crossref
Crossref
Viktor Grünwald, Thomas Powles, Toni K Choueiri, Thomas E Hutson, Camillo Porta, Masatoshi Eto, Cora N Sternberg, Sun Young Rha, Cixin S He, Corina E Dutcus, Alan Smith, Lea Dutta, Kalgi Mody & Robert J Motzer. (2019) Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale. Future Oncology 15:9, pages 929-941.
Crossref
Crossref
Valentina Poletto, Vittorio Rosti, Marco Biggiogera, Germano Guerra, Francesco Moccia & Camillo Porta. (2018) The role of endothelial colony forming cells in kidney cancer’s pathogenesis, and in resistance to anti-VEGFR agents and mTOR inhibitors: A speculative review. Critical Reviews in Oncology/Hematology 132, pages 89-99.
Crossref
Crossref
Vikas Dembla, Roman Groisberg, Ken Hess, Siqing Fu, Jennifer Wheler, David S. Hong, Filip Janku, Ralph Zinner, Sarina Anne Piha-Paul, Vinod Ravi, Robert S. Benjamin, Shreyaskumar Patel, Neeta Somaiah, Cynthia E. Herzog, Daniel D. Karp, Jason Roszik, Funda Meric-Bernstam & Vivek Subbiah. (2017) Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. Scientific Reports 7:1.
Crossref
Crossref
Matthew R. Lowerison, Ann F. Chambers, Hon S. Leong, Nicholas E. Power & James C. Lacefield. (2017) Reduced variability of CEUS perfusion estimates in a patient-derived xenograft model via analysis of speckle statistics. Reduced variability of CEUS perfusion estimates in a patient-derived xenograft model via analysis of speckle statistics.
Alessia Mennitto, Paolo Grassi, Raffaele Ratta, Elena Verzoni, Michele Prisciandaro & Giuseppe Procopio. (2016) Nivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience. Therapeutic Advances in Urology 8:5, pages 319-326.
Crossref
Crossref
Amaury Daste, Marine Gross-Goupil, Amandine Quivy, Louis François, Jean-Christophe Bernhard & Alain Ravaud. (2016) Efficacy of Rechallenge of Metastatic Renal Cell Carcinoma Patient With Sunitinib After Prior Resistance to Axitinib: Case Report and Review of the Literature. Clinical Genitourinary Cancer 14:5, pages e525-e527.
Crossref
Crossref
Glenda C. Gobe, Keng Lim Ng, David M. Small, David A. Vesey, David W. Johnson, Hemamali Samaratunga, Kimberley Oliver, Simon Wood, Johanna L. Barclay, Retnagowri Rajandram, Li Li & Christudas Morais. (2016) Decreased apoptosis repressor with caspase recruitment domain confers resistance to sunitinib in renal cell carcinoma through alternate angiogenesis pathways. Biochemical and Biophysical Research Communications 473:1, pages 47-53.
Crossref
Crossref
Yi Sun, Wei Zhang, Yunqin Chen, Qin Ma, Jia Wei & Qi Liu. (2016) Identifying anti-cancer drug response related genes using an integrative analysis of transcriptomic and genomic variations with cell line-based drug perturbations. Oncotarget 7:8, pages 9404-9419.
Crossref
Crossref
S. Bracarda. (2016) More colors to the palette. Annals of Oncology 27:2, pages 363.
Crossref
Crossref
Francesco Moccia & Germano Guerra. (2016)
Ca
2+
Signalling in Endothelial Progenitor Cells: Friend or Foe?
. Journal of Cellular Physiology 231:2, pages 314-327.
Crossref
Crossref
Véronique Mathieu, Aurélie Chantôme, Florence Lefranc, Alessio Cimmino, Walter Miklos, Verena Paulitschke, Thomas Mohr, Lucia Maddau, Alexander Kornienko, Walter Berger, Christophe Vandier, Antonio Evidente, Eric Delpire & Robert Kiss. (2015) Sphaeropsidin A shows promising activity against drug-resistant cancer cells by targeting regulatory volume increase. Cellular and Molecular Life Sciences 72:19, pages 3731-3746.
Crossref
Crossref
Christopher JedeszkoMarta Paez-RibesTeresa Di DesideroShan ManChristina R. LeePing XuGeorg A. BjarnasonGuido BocciRobert S. Kerbel. (2015) Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib. Science Translational Medicine 7:282.
Crossref
Crossref
R. Rajandram, N.Y. Yap, J. Pailoor, A.H.A. Razack, K.L. Ng, T.A. Ong, C. Morais & G.C. Gobe. (2014) Tumour necrosis factor receptor-associated factor-1 (TRAF-1) expression is increased in renal cell carcinoma patient serum but decreased in cancer tissue compared with normal: potential biomarker significance. Pathology 46:6, pages 518-522.
Crossref
Crossref
C Porta, C Paglino & V Grünwald. (2014) Sunitinib re-challenge in advanced renal-cell carcinoma. British Journal of Cancer 111:6, pages 1047-1053.
Crossref
Crossref
Silvia Dragoni, Ilaria Turin, Umberto Laforenza, Duilio Michele Potenza, Cinzia Bottino, Toma N. Glasnov, Martina Prestia, Federica Ferulli, Anna Saitta, Alessandra Mosca, Germano Guerra, Vittorio Rosti, Ombretta Luinetti, Carlo Ganini, Camillo Porta, Paolo Pedrazzoli, Franco Tanzi, Daniela Montagna & Francesco Moccia. (2014)
Store-Operated Ca
2+
Entry Does Not Control Proliferation in Primary Cultures of Human Metastatic Renal Cellular Carcinoma
. BioMed Research International 2014, pages 1-19.
Crossref
Crossref
Sergio BracardaRodolfo Montironi, Camillo Porta, Cezary Szczylic, Alessandra Bearz, Giacomo Cartenì & Joaquim Bellmunt. (2013) The treating scenario in genitourinary oncology: what is new? Part 1. Future Oncology 9:6, pages 797-801.
Crossref
Crossref